Plant ID: NPO26293
Plant Latin Name: Ginkgo biloba
Taxonomy Genus: Ginkgo
Taxonomy Family: Ginkgoaceae
NCBI TaxonomyDB:
3311
Plant-of-the-World-Online:
262125-1
Antianxiety; Antiasthmatic; Antibacterial; Antifungal; Astringent; Cancer; Digestive; Expectorant; Infertility; Ophthalmic; Sedative; Tonic; Vermifuge
South Africa; Indonesia; India; United States; China; Thailand; Japan; South Korea
ADORA3; PTAFR; FFAR1; FFAR4; ADRA2B; | |
GRM1; GRM8; | |
TSHR; OPRD1; NPSR1; | |
ACHE; | |
RECQL; ALPL; TDP1; BLM; PKM; TERT; TK1; GLO1; PGD; ALOX12; HSD17B1; HSD17B2; HSD17B10; NOX4; ALOX15; APEX1; AOX1; POLB; | |
BCL2; | |
GLRA1; | |
GRIA4; GRIA2; GRIK3; GRIK5; GRIK1; | |
GABRR1; | |
TOP2A; | |
PIM1; AXL; IGF1R; FLT3; CDK1; EGFR; MET; KDR; CDK8; AURKB; CSNK2A1; | |
CA2; CA12; CA14; CA7; CA4; | |
ESR1; ESR2; | |
ESRRB; ESRRA; | |
TYR; | |
BACE1; | |
MMP9; MMP12; MMP2; MMP1; | |
HIF1A; NFKB1; AHR; | |
KMT2A; | |
DNMT1; | |
ABCB1; | |
SLC1A1; SLCO1B1; | |
LMNA; FABP3; FABP4; MAPT; THPO; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
Glycine receptor | GLRA1 | Glycine receptor subunit alpha-1 | P23415 | CHEMBL5845 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | PTAFR | Platelet activating factor receptor | P25105 | CHEMBL250 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.895E-11 | 2.948E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
MF | Unclassified; | GO:0004872; receptor activity | 4.549E-11 | 5.827E-08 | ADORA3, ADRA2B, AHR, AXL, EGFR, ESR1, ESR2, ESRRA, ESRRB, FFAR1, FFAR4, FLT3, GABRR1, GLRA1, GRIA2, GRIA4, GRIK1, GRIK3, GRIK5, GRM1, GRM8, IGF1R, KDR, MET, NPSR1, OPRD1, PTAFR, TSHR |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.627E-10 | 3.949E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.817E-09 | 1.319E-06 | BLM, CA12, CA2, CA4, CA7, DNMT1, ESR1, ESR2, ESRRA, ESRRB, GLO1, GLRA1, KMT2A, L3MBTL1, MMP1, MMP12, MMP2, MMP9, TK1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.104E-09 | 1.439E-06 | ALOX12, ALOX15, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.249E-09 | 2.500E-06 | CA12, CA14, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.203E-09 | 2.905E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 1.623E-08 | 6.666E-06 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.820E-08 | 1.059E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.631E-08 | 1.551E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 7.187E-08 | 2.204E-05 | ABCB1, CA2, CA7, PTAFR |
BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 8.960E-08 | 2.439E-05 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
MF | GO:0005488; binding | GO:0020037; heme binding | 9.361E-08 | 2.517E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 1.594E-07 | 3.829E-05 | ALOX12, AURKB, AXL, BCL2, CDK1, CSNK2A1, EGFR, FFAR4, GLO1, HIF1A, IGF1R, KDR, LMNA, MMP9, NFKB1, PIM1, TERT |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.683E-07 | 3.940E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.687E-07 | 5.851E-05 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.279E-07 | 6.736E-05 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.919E-07 | 7.620E-05 | ALPL, APEX1, BLM, CYP1A1, CYP1B1, EGFR, ESR1, FLT3, NFKB1, NOX4, PTAFR |
BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 5.831E-07 | 1.058E-04 | GLRA1, GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 8.172E-07 | 1.401E-04 | GRIK1, GRIK3, GRIK5 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.038E-06 | 1.725E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3, PKM |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.390E-06 | 2.193E-04 | CA12, CA14, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 2.154E-06 | 3.191E-04 | CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1 |
CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 4.154E-06 | 5.483E-04 | GABRR1, GLRA1, GRIA2, GRIA4, GRIK1, GRIK3, GRIK5, OPRD1 |
BP | GO:0023052; signaling | GO:0051966; regulation of synaptic transmission, glutamatergic | 6.085E-06 | 7.528E-04 | EGFR, GRIK1, GRIK3, GRM1, GRM8 |
BP | GO:0008152; metabolic process | GO:0031328; positive regulation of cellular biosynthetic process | 6.303E-06 | 7.754E-04 | AHR, AURKB, BLM, CDK1, CDK8, EGFR, ESR1, ESR2, ESRRA, ESRRB, FABP3, HIF1A, IGF1R, KMT2A, MET, MMP12, NFKB1, NOX4, PTAFR, TERT, TOP2A, TSHR |
BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 6.777E-06 | 8.199E-04 | GRIK3, GRM1, GRM8 |
BP | GO:0008152; metabolic process | GO:0010557; positive regulation of macromolecule biosynthetic process | 7.732E-06 | 9.200E-04 | AHR, AURKB, BLM, CDK1, CDK8, EGFR, ESR1, ESR2, ESRRA, ESRRB, HIF1A, IGF1R, KDR, KMT2A, MET, MMP12, NFKB1, NOX4, PTAFR, TERT, TOP2A |
BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 1.108E-05 | 1.257E-03 | ALOX15, ALPL, BCL2, EGFR, MMP2, MMP9 |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.204E-05 | 1.338E-03 | AHR, EGFR, GABRR1, GRIA2, GRIA4, GRIK5, GRM1, IGF1R, TSHR |
BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 1.224E-05 | 1.353E-03 | AXL, BCL2, FLT3, HIF1A, KMT2A, POLB |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 1.402E-05 | 1.526E-03 | ACHE, ADORA3, ALOX15, BCL2, CDK1, CYP1A1, EGFR |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.758E-05 | 1.877E-03 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0051179; localization | GO:0051050; positive regulation of transport | 1.847E-05 | 1.953E-03 | ABCB1, ACHE, AXL, BCL2, CA2, CDK1, CYP19A1, EGFR, FFAR1, HIF1A, KMT2A, MMP12, NPSR1, PTAFR, TERT |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.847E-05 | 1.953E-03 | CA12, CA2, CA4, CA7 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.914E-05 | 1.966E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.914E-05 | 1.966E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.914E-05 | 1.966E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.914E-05 | 1.966E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.278E-05 | 2.307E-03 | CYP19A1, HSD17B1, HSD17B2 |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 2.459E-05 | 2.457E-03 | ACHE, APEX1, CSNK2A1, EGFR, ESRRB, FLT3, IGF1R, KDR, L3MBTL1, MAPT, MMP12, MMP9, PIM1, PKM, TSHR |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 2.517E-05 | 2.503E-03 | AURKB, CSNK2A1, EGFR, FLT3, IGF1R, KDR, PIM1 |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 3.576E-05 | 3.415E-03 | AHR, AXL, BCL2, CSNK2A1, EGFR, ESR1, KMT2A, TOP2A |
MF | GO:0005488; binding | GO:0042562; hormone binding | 3.645E-05 | 3.466E-03 | ACHE, EGFR, HSD17B1, IGF1R, PKM |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 3.857E-05 | 3.652E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
BP | GO:0032501; multicellular organismal process | GO:0048546; digestive tract morphogenesis | 4.419E-05 | 4.077E-03 | BCL2, EGFR, HIF1A |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.725E-05 | 5.006E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 5.725E-05 | 5.006E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 5.725E-05 | 5.006E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 5.725E-05 | 5.006E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 7.496E-05 | 6.401E-03 | CDK1, CDK8, ESR1, ESR2, ESRRA, ESRRB |
BP | GO:0032501; multicellular organismal process | GO:0035162; embryonic hemopoiesis | 7.573E-05 | 6.403E-03 | HIF1A, KDR, KMT2A |
BP | GO:0000003; reproduction | GO:0022414; reproductive process | 7.587E-05 | 6.403E-03 | ADRA2B, ALPL, AXL, BCL2, CDK1, CYP19A1, CYP1A1, EGFR, ESR1, ESRRB, GLRA1, HIF1A, HSD17B2, MMP2, MMP9, PTAFR, TOP2A |
BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 7.965E-05 | 6.670E-03 | ALOX15, AURKB, BCL2, DNMT1, HIF1A, KDR, KMT2A, MAPT, MET, MMP9, NOX4 |
BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 8.881E-05 | 7.243E-03 | EGFR, ESRRB, HIF1A |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 8.881E-05 | 7.243E-03 | AHR, ESR1, TERT |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 9.573E-05 | 7.664E-03 | BCL2, HIF1A, LMNA, OPRD1, TERT |
BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 9.888E-05 | 7.887E-03 | AURKB, BCL2, BLM, EGFR, HIF1A, KMT2A, NOX4, POLB, TYR |
BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 1.014E-04 | 8.028E-03 | BCL2, CYP1B1, EGFR, HIF1A, MAPT, NOX4 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.048E-04 | 8.236E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
BP | GO:0051179; localization | GO:1901529; positive regulation of anion channel activity | 1.142E-04 | 8.745E-03 | ABCB1, PTAFR |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.142E-04 | 8.745E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.142E-04 | 8.745E-03 | ESR1, ESR2 |
MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 1.142E-04 | 8.745E-03 | GRIA2, GRIA4 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.192E-04 | 9.045E-03 | MMP2, MMP9, TERT |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.228E-04 | 9.283E-03 | AHR, ESR1, ESR2, ESRRA, ESRRB, PIM1 |
BP | GO:0051179; localization | GO:0034502; protein localization to chromosome | 1.322E-04 | 9.863E-03 | AURKB, CDK1, ESR1, TERT |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.087E-11 | 1.836E-09 | OPRD1, GRIA2, GRIK5, PTAFR, GRIK3, GRIK1, ADRA2B, TSHR, GRM1, GLRA1, GABRR1, ADORA3, GRM8, GRIA4 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 4.914E-09 | 4.122E-07 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
09150 Organismal Systems | 09156 Nervous system | hsa04724 | Glutamatergic synapse | 2.904E-08 | 1.227E-06 | GRIA2, GRIK5, SLC1A1, GRM8, GRIK3, GRIK1, GRM1, GRIA4 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 6.740E-08 | 2.278E-06 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.316E-09 | 4.122E-07 | CA12, CA2, CA4, CA7, CA14 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.419E-06 | 5.110E-05 | MMP2, KDR, HIF1A, ESR1, MMP9, MET, EGFR, IGF1R |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 3.641E-06 | 6.804E-05 | DNMT1, ALOX15, ALOX12, CYP2C19, PGD, CYP3A4, TYR, CYP19A1, HSD17B10, CYP2C9, PKM, HSD17B1, HSD17B2, CYP1A2, CYP1A1, ALPL, AOX1, TK1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.349E-07 | 3.800E-06 | CYP2C9, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 7.055E-06 | 9.935E-05 | FLT3, MMP1, MMP2, BCL2, HIF1A, MET, MMP9, EGFR, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 4.026E-06 | 6.804E-05 | MMP2, ESR1, MMP9, EGFR, ESR2, GRM1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.333E-06 | 3.217E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.771E-06 | 7.329E-05 | DNMT1, ABCB1, PIM1, BCL2, CYP1B1, MMP9, MET, EGFR, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 9.666E-06 | 1.167E-04 | PKM, FLT3, MET, HIF1A, EGFR |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 8.322E-06 | 1.082E-04 | CYP2C9, CYP1A2, CYP1A1, AOX1, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.117E-05 | 1.259E-04 | CYP2C9, CYP1A2, AOX1, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.474E-05 | 1.556E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.773E-05 | 6.914E-04 | BCL2, HIF1A, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.187E-04 | 1.003E-03 | KMT2A, FLT3, MMP9, MET, NFKB1, IGF1R |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.471E-05 | 2.456E-04 | CYP1A2, CYP1A1, AOX1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.729E-05 | 2.562E-04 | MMP1, MMP2, MMP9, EGFR |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.405E-04 | 1.130E-03 | CYP2C9, ALOX15, ALOX12, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.636E-04 | 3.968E-03 | BCL2, EGFR, NFKB1, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.787E-04 | 2.048E-03 | CSNK2A1, MET, EGFR, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 9.067E-04 | 5.675E-03 | MMP2, PIM1, BCL2, NFKB1 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.377E-04 | 1.826E-03 | SLCO1B1, ABCB1, CA2, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 9.067E-04 | 5.675E-03 | GRIA2, GABRR1, GRM1, GRIA4 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.706E-03 | 9.668E-03 | KDR, BCL2, MET, EGFR, IGF1R |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.331E-03 | 8.036E-03 | CYP2C9, ALOX15, ALOX12, CYP2C19 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.716E-03 | 9.668E-03 | OPRD1, ADORA3, BCL2, NFKB1 |
09160 Human Diseases | 09164 Substance dependence | hsa05033 | Nicotine addiction | 6.534E-04 | 4.417E-03 | GRIA2, GABRR1, GRIA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM; |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | PTAFR; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; TERT; FLT3; TK1; DNMT1; |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
NA: NA | Acute nonspecific diarrhea | NA | OPRD1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; PTAFR; EGFR; BCL2; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; TERT; FLT3; TK1; EGFR; BCL2; |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PTAFR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; MMP2; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | PTAFR; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | GRIK1; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; GRM1; CDK1; IGF1R; ACHE; OPRD1; PTAFR; GRIK1; PKM; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; TK1; HIF1A; PTAFR; MMP9; EGFR; PKM; MMP2; ABCB1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; ALPL; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; FFAR1; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; DNMT1; EGFR; ABCB1; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; PTAFR; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; DNMT1; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR; BCL2; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; ESRRA; |
A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | PTAFR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; BCL2; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; ESRRA; MMP1; TYR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | GRM1; ADRA2B; GRIK1; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; KDR; EGFR; MMP2; ABCB1; |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
NA: NA | Hepatitis C virus infection | NA | ADORA3; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; KDR; FLT3; TK1; EGFR; MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; GRIA2; GRIA4; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
NA: NA | HIV infections | NA | AHR; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTAFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; ABCB1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Ocular allergy | H00-H59 | PTAFR; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
NA: NA | Edema | NA | CA2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; MMP1; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; TERT; AHR; BCL2; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; EGFR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA3; |
NA: NA | GIST | NA | FLT3; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PTAFR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; KDR; EGFR; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ESRRA; PTAFR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; TERT; TK1; EGFR; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; TERT; KDR; FLT3; EGFR; CYP19A1; BCL2; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | PTAFR; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; EGFR; |
H00-H59: Diseases of the eye and adnexa | Conjunctivitis | H10 | PTAFR; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | PTAFR; MMP9; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; GRM1; NPSR1; GRIK1; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; BCL2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; TERT; KDR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GRM1; ACHE; MAPT; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PTAFR; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | PTAFR; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; OPRD1; GRIK1; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1; |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; OPRD1; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
NA: NA | Menopausal disorder | NA | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | TERT; KDR; EGFR; TYR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; EGFR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; TK1; ACHE; HIF1A; ADORA3; DNMT1; MMP9; EGFR; MMP2; ABCB1; BCL2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; ABCB1; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |